Chapter
Publicly Available
Contents
-
Margaret Eaton
Chapters in this book
- Frontmatter i
- Contents vii
- Acknowledgments xi
- Preface xv
-
Part I. Introduction
- Introduction 1
-
Part II. Ethics and Industry Overview
- 2. Ethics and Business Activity 21
- 3. Ethics Analysis Applied to Monsanto and the Labeling of rbST 70
- 4. Research Ethics 106
- 5. Industry Regulation and the Product Approval Process 129
-
Part III. Case Studies
- Research Collaborations Between Academia and Industry 149
- 7. Industry-Sponsored Clinical Research and the Use of Placebo Controls 195
- 8. Mitigation of Harm to Subjects Injured in Clinical Research 235
- 9. Conducting Clinical Research in Developing Countries 276
- 10. Anticipating and Managing Postmarket Problems 329
- 11. Access to Medical Products 377
- 12. Advertising Prescription Drugs Directly to Patients 427
- 13. Using Corporate Ethics Advice 480
- Index 519
Chapters in this book
- Frontmatter i
- Contents vii
- Acknowledgments xi
- Preface xv
-
Part I. Introduction
- Introduction 1
-
Part II. Ethics and Industry Overview
- 2. Ethics and Business Activity 21
- 3. Ethics Analysis Applied to Monsanto and the Labeling of rbST 70
- 4. Research Ethics 106
- 5. Industry Regulation and the Product Approval Process 129
-
Part III. Case Studies
- Research Collaborations Between Academia and Industry 149
- 7. Industry-Sponsored Clinical Research and the Use of Placebo Controls 195
- 8. Mitigation of Harm to Subjects Injured in Clinical Research 235
- 9. Conducting Clinical Research in Developing Countries 276
- 10. Anticipating and Managing Postmarket Problems 329
- 11. Access to Medical Products 377
- 12. Advertising Prescription Drugs Directly to Patients 427
- 13. Using Corporate Ethics Advice 480
- Index 519